{"id":"W2963065632","doi":"10.1016/j.euo.2019.06.018","title":"Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Meso Scale Diagnostics; Novartis Pharma; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; AstraZeneca; Ipsen; Bayer Schering; Novartis; Pfizer; Bristol-Myers Squibb","keywords":"Temsirolimus; Sunitinib; Medicine; Everolimus; Internal medicine; Renal cell carcinoma; Oncology; Discovery and development of mTOR inhibitors; Refractory (planetary science); Pazopanib; Sorafenib; Tyrosine-kinase inhibitor; Progressive disease; Cancer; Progression-free survival; Urology; PI3K/AKT/mTOR pathway; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000745516,0.0004506369,0.0009197371,0.0004830744,0.00008912144,0.00006733123,0.0003941266,0.0001253512,0.001685878],"category_scores_gemma":[0.000139402,0.0003813785,0.0002017837,0.0004046096,0.0001550503,0.0001856502,0.000388044,0.0005216371,0.01587471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003665072,"about_ca_system_score_gemma":0.0003738803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001477767,"about_ca_topic_score_gemma":0.000008092056,"domain_scores_codex":[0.995728,0.001432054,0.000615121,0.0009938384,0.0003075746,0.0009233949],"domain_scores_gemma":[0.9973933,0.000385062,0.0002189732,0.0009542469,0.0002433131,0.0008051826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02381909,0.005630773,0.06730185,0.0006395025,0.001511749,0.1286879,0.02571786,0.001214084,0.340244,0.001299443,0.06573085,0.3382029],"study_design_scores_gemma":[0.01344336,0.07593579,0.240853,0.00009499797,0.001146782,0.00541335,0.002869746,0.00005066337,0.02103237,0.00006521375,0.6380826,0.001012138],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9186346,0.002003231,0.00005583121,0.006133082,0.0008545986,0.00221487,0.000007121414,0.0001023893,0.06999426],"genre_scores_gemma":[0.9747337,0.00003428537,0.003357676,0.01767012,0.000362145,0.000101054,0.00005967909,0.0001311242,0.003550191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5723518,"threshold_uncertainty_score":0.9998638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03048655956001292,"score_gpt":0.2902919945344529,"score_spread":0.25980543497444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}